Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.02
-$0.14-2.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 152.43% | -32.19% | 52.12% | -170.49% | 25.90% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -1.61% | -0.80% | 0.80% |
| Total Amortization of Deferred Charges | -15.38% | -16.13% | -15.07% | -12.05% | -3.49% |
| Total Other Non-Cash Items | -300.29% | 147.06% | -80.87% | 1,250.66% | -35.04% |
| Change in Net Operating Assets | -345.63% | -11.97% | 91.38% | 126.22% | -205.32% |
| Cash from Operations | -48.19% | 11.55% | -6.05% | 26.55% | -13.69% |
| Capital Expenditure | 0.00% | -- | 100.00% | 14.29% | 85.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -- | 100.00% | 14.29% | 74.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | -49.97% | -- |
| Issuance of Common Stock | -99.33% | 2,160.31% | -6.03% | 978.88% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -102.03% | 5,380.80% | -13.78% | 254.98% | -937.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.18% | 1,858.50% | -14.96% | 56.09% | -28.14% |